Welcome to our dedicated page for Visionary Holdings news (Ticker: GV), a resource for investors and traders seeking the latest updates and insights on Visionary Holdings stock.
Visionary Holdings Inc. reports developments tied to its healthcare, biotechnology, and medical-aesthetics focus, including commercialization activity for anti-aging and regenerative wellness products. Company updates have covered V-series anti-aging products, RAMU-related products, Premier Regenerative Complex-President Super Injection, distribution arrangements, channel development, and healthcare service collaborations in markets including China.
Recurring news also includes Nasdaq listing-compliance matters for GV common shares, periodic reporting status, listing-fee notices, shareholder voting matters, governance actions, capital-structure disclosures, and operating and financial results.
Visionary Holdings (NASDAQ: GV) received a Nasdaq staff determination letter dated April 29, 2026, notifying the company of noncompliance with Nasdaq Listing Rule 5250(f) due to delinquent annual listing fees of approximately US$35,000. Nasdaq warned of suspension on May 8, 2026 and filing Form 25-NSE unless a hearing was requested by May 6, 2026. Following receipt of the notice, the company paid the outstanding fee and is working with Nasdaq on the matter. The company said it remains committed to maintaining compliance and will provide updates as appropriate. This disclosure is made under Nasdaq Listing Rule 5810(b).
Visionary Holdings (NASDAQ: GV) received a Nasdaq notification dated April 7, 2026, for non‑compliance with the $1.00 minimum bid rule after the closing bid was below $1.00 for 30 consecutive business days from February 23 to April 6, 2026. Trading of GV continues on the Nasdaq Capital Market.
The company has an initial 180‑calendar‑day compliance period until October 5, 2026 to regain compliance by achieving a $1.00 closing bid for ten consecutive business days, or seek an additional cure period or consider a reverse stock split.
Visionary Holdings (Nasdaq: GV) received a Nasdaq Deficiency Letter on April 2, 2026 for failure to timely file Form 6-K including interim financial statements, triggering non‑compliance with Nasdaq Rule 5250(c)(1).
The company has until June 1, 2026 to submit a compliance plan; Nasdaq may extend the cure period to September 28, 2026 if a plan is accepted. Trading continues on Nasdaq while the company works to complete the Required Filing and regain compliance.
Visionary Holdings (NASDAQ: GV) signed an Investment Cooperation Agreement for a proposed US$20 million strategic investment to advance a Qingdao anti-aging project in Qingdao West Coast New Area, China. The plan calls for a project company, a GV China Anti-Aging Research Center, and a GV Anti-Aging Health Management Center chain.
The investor intends to invest no less than US$20 million in two phases, with an initial milestone-based phase (payments of 30%/40%/30%) and a contemplated second-phase US$10 million. Progress remains subject to definitive agreements, due diligence, regulatory steps, and customary closing conditions.
Visionary Holdings (NASDAQ: GV) entered a strategic cooperation agreement with Zhejiang Chushanji Digital Technology to expand distribution of its V-series anti-aging products in China.
Chushanji operates an offline network across 5 provinces and ~10,000 stores. Visionary projects a preliminary potential annual revenue range of $10M–$15M, but notes the collaboration is at an initial stage and outcomes are uncertain due to market, execution, channel, and regulatory risks.
Visionary Holdings (NASDAQ: GV) announced a US$12 million exclusive distribution agreement with Huajin China for its flagship Premier Regenerative Complex – President Super Injection, targeting minimum contracted sales within 12 months. The Board approved a divestiture of 100% equity in Visionary Education Services & Management, refocusing the company on medical aesthetics and biotechnology.
Revenue recognition is subject to delivery, customer acceptance, and accounting standards. The company said the moves accelerate commercialization and concentrate capital and management on high-margin regenerative aesthetic products.
Visionary Holdings (NASDAQ: GV) provided a 2026–2027 business outlook, emphasizing a strategic shift into higher‑margin healthcare services and medical aesthetics. Management said commercialization of the RAMU anti‑aging product line could potentially reach approximately US$30 million in annual sales, subject to market conditions, regulatory approvals, and execution.
The company plans continued expansion into North America and Europe via product commercialization, distribution partnerships, and healthcare service collaborations, and intends to develop an integrated healthcare services platform combining products, wellness services, and biotechnology.
Visionary Holdings (NASDAQ: GV) signed an exclusive distribution agreement with Huajin China for its Premier Regenerative Complex – President Super Injection, establishing a minimum contracted sales target of US$12 million within 12 months.
On February 27, 2026, the Board approved divestiture of its education business, refocusing the company on medical aesthetics, anti-aging injectables, and biotechnology-driven healthcare.
Visionary Holdings (NASDAQ: GV) said its subsidiary GV Hong Kong is executing a previously signed commercial sales agreement with a total contract value of approximately US$9 million (signed September 2025).
Early-stage service activities are underway and the company expects further substantive execution milestones by the end of the first quarter of 2026, with revenue recognition and cash collection following contractual terms and applicable accounting standards.
Visionary Holdings (Nasdaq: GV) announced that its subsidiary Visionary Health Technology Group established three wholly owned regional subsidiaries in Qingdao, Wuxi and Wuhu on Feb. 18, 2026 to drive localized commercial expansion for regenerative medicine, cellular rejuvenation and aesthetic treatment products.
The move builds on GV’s Asia headquarters in Hangzhou and sales entity in Nanjing, creating a multi-city commercialization network to support localized sales teams, institutional partnerships, product deployment, and improved revenue visibility.